Arcus Biosciences (NYSE:RCUS) appointed Eric Hoefer as its chief commercial officer to oversee the company’s global commercial strategy and operations.
Raymond James named finance professional, Andrew Gitkin, as managing director and co-head of the firm’s health care investment banking practice, along side managing director, Riley Sweat.
Spectrum Therapeutics, the medical division of Canopy Growth (TSX:WEED; NYSE:CGC) appointed Dr. Marcel Bonn-Miller as global clinical scientific director.
Canopy Growth (TSX:WEED; NYSE:CGC) appointed Mike Lee as acting CFO, effective June 1, and subject to Health Canada security clearance required for all officers and directors of the company.
Zenabis Global (TSXV:ZENA) provide an update on its recent cannabis production figures, anticipated future harvests, facility construction and licensing status, and medical program update.
Neptune Wellness Solutions (NASDAQ:NEPT; TSX:NEPT) appointed Martin Landry to the new position of chief of corporate development and strategy, effective May 27.
MediPharm Labs (TSXV:LABS; OTCQB:MEDIF) appointed Braden Fenske as chief strategy officer and Dr. Paul Tam to its board of directors, effective immediately.
BriaCell Therapeutics (TSV-V:BCT; OTCQB:BCTXF) appointed Dr. Rebecca Taub and Vaughn Embro-Pantalony as directors, and current board members Dr. Saeid Babaei, Rahoul Sharan, and Martin Schmieg have resigned, effective...
Roth Capital Partners appointed Charles “Tony” Butler as a managing director, senior research analyst and head of biotechnology research, and a partner.
BioSig Technologies (NASDAQ:BSGM) named John Kowalski as VP of sales to lead the commercial launch of the PURE EP signal acquisition and processing system, which is designed to improve the diagnosis and treatment of...
Closely-held Ocutrx Vision Technologies appointed Dr. Linda Lam as chief scientific and strategy officer to guide new technology development, and help align current and future R&D efforts, industry trends and growth...
Prometic Life Sciences (TSX:PLI; OTCQX:PFSCF) named Prof. Simon Best as interim CEO, effective immediately, succeeding Pierre Laurin, who has stepped down from his management and board responsibilities.